Alexander Olawaiye
UPMC Hillman Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alexander Olawaiye as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:26 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05200559 · T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid TumorsAlexander B Olawaiye, MD · active not recruiting · Epithelial Ovarian Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:26 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.Lancet Oncol · 2020202 citationsRCR 7.7
- 182 citationsRCR 8.8
- Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.Gynecol Oncol · 201271 citationsRCR 1.9
- 61 citationsRCR 13.8
- Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.J Clin Oncol · 202344 citationsRCR 3.4
- Three-dimensional image-based high-dose-rate interstitial brachytherapy for vaginal cancer.Brachytherapy · 201230 citationsRCR 1.2
- Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial.Nat Commun · 202523 citationsRCR 4.9
- Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.Nat Med · 202522 citationsRCR 4.1
- 21 citationsRCR 0.7
- 18 citationsRCR 1.0